Production (Stage)
XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 76.86% | -95.46% | 55.98% | 110.05% | -64.79% |
| Total Depreciation and Amortization | -19.00% | 6.97% | 56.97% | 3.13% | -51.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -111.84% | 78.86% | -1,131.25% | -6,202.29% | 7,875.40% |
| Change in Net Operating Assets | 181.65% | 33.96% | -74.48% | 790.26% | 56.13% |
| Cash from Operations | 50.63% | 31.72% | 29.77% | 57.41% | 47.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.77% | 59.18% | -217.81% | -15.19% | 84.80% |
| Cash from Investing | -30.77% | 59.18% | -217.81% | 4.21% | 86.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -45.28% | -33.53% | -32.93% | 45.73% | 1.24% |
| Issuance of Common Stock | -94.37% | -- | -- | -- | 672,266.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.34% | -25.40% | -- | -100.00% | -4,700.00% |
| Cash from Financing | -96.03% | 454.47% | -32.93% | 11.88% | 7,843.64% |
| Foreign Exchange rate Adjustments | 111.83% | -2,813.33% | 9,850.00% | -154.35% | -875.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -249.15% | 110.66% | 28.97% | 56.60% | 115.35% |